The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Moving away from FISH and towards NGS for genetic testing in multiple myeloma
In this video, Jonathan Keats, PhD, Translational Genomics Research Institute, Phoenix, AZ, briefly comments on the importance of transitioning from fluorescent in-situ hybridization (FISH) to next-generation sequencing (NGS) for genetic testing in multiple myeloma (MM). Dr Keats highlights the need to establish gold standards for positive controls for assay development and to understand the various tools and techniques that can be used to further the understanding of myeloma disease biology. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
